Abstract：
Aim: To assess the effectiveness of different types of taxanes, including nab-paclitaxel, paclitaxel and docetaxel, and further compare the effectiveness of taxane-based chemotherapy, taxane-based chemotherapy plus angiogenesis inhibitors or taxane-based chemotherapy plus immune checkpoint inhibitors in HER2-altered non-small-cell lung cancer in the second- or third-line setting. Materials & methods: A total of 52 patients were included in the study. Progression-free survival was compared between subgroups. Results: A clinically meaningful improvement in progression-free survival was observed among patients in the nab-paclitaxel group compared with the docetaxel group. Taxane-based chemotherapy plus immune checkpoint inhibitors achieved longer progression-free survival than taxane-based chemotherapy. There was no difference between taxane-based chemotherapy plus immune checkpoint inhibitors and taxane-based chemotherapy plus angiogenesis inhibitors. Conclusion: Nab-paclitaxel appears to be a reasonable alternative to docetaxel. Chemotherapy plus immune checkpoint inhibitors might yield more survival benefits than chemotherapy alone.
摘要：
目的：评估不同类型紫杉烷的有效性，包括nab-紫杉醇,紫杉醇和多西他赛，并进一步比较基于紫杉烷的化疗的有效性，基于紫杉烷的化疗加血管生成抑制剂或基于紫杉烷的化疗加免疫检查点抑制剂治疗HER2改变的非小细胞肺癌的二线或三线治疗.材料与方法：本研究共纳入52例患者。比较亚组之间的无进展生存期。结果：与多西他赛组相比，nab-紫杉醇组患者的无进展生存期有临床意义的改善。基于紫杉烷的化疗加免疫检查点抑制剂比基于紫杉烷的化疗获得更长的无进展生存期。基于紫杉烷的化疗加免疫检查点抑制剂与基于紫杉烷的化疗加血管生成抑制剂之间没有差异。结论：Nab-紫杉醇似乎是多西他赛的合理替代方案。化疗加免疫检查点抑制剂可能比单独化疗产生更多的生存益处。
